Psilocybin Microdosing

(See Part 1: Exclusive Insights: How Tech Leaders Are Finding Balance Through Microdosing Psychedelics) Paul Austin, the trainer of psychedelics microdosing practitioners, spoke to Benzinga about his collaboration with Lauren Mugglebee, who transitioned from a career at Meta  (NASDAQ: META)...

Biopharma company Apex Labs Ltd. has completed one of the first take-home microdose psilocybin clinical trials, meeting all study endpoints over a two-month period with no adverse events reported. CEO Tyler Powell called it a clinical milestone and said he's certain it will help the...

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a genetic disorder. KGK and its client Nova Mentis (OTC: NMLSF) are set to conduct this pioneering...

Nova Mentis Life Science Corp. (OTCQB: NMLSF), a biotech company focused on creating psilocybin-based therapeutics produced 1.5 mg psilocybin microdose capsules compliant with the chemistry, manufacturing and controls (CMC) published guidelines. NOVA’s new compounds would be used in...

(Part two of a four-part series) Regarding small psilocybin doses, a recently published crowd-sourced research site found that 953 people who microdose showed on average greater improvement in mental health and mood over one month compared to 180 who do not microdose. As a...